Combined intracameral and intravitreal bevacizumab injection in Neovascular Glaucoma
Journal of the Egyptian Ophthalmological Society · 2013
DOI: 10.4103/2090-0686.127340 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the Egyptian Ophthalmological Society, 2013. Verfasst von Abeer Khattab und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
PurposeThe aim of this study was to assess the efficacy and safety of combined intracameral and intravitreal injection of bevacizumab followed by panretinal photocoagulation (PRP) in the treatment of neovascular glaucoma.DesignThis study is a prospective, interventional case series.Patients and methodsThis study is prospective observational case series of 23 eyes of 23 patients with different degrees of neovascular glaucoma (>22 mmHg) treated with simultaneous combined intracameral and intravitreal bevacizumab injection followed by PRP. Duration of follow-up was 3 months. The outcome measures were neovascular membrane extent, best corrected visual acuity (BCVA), and intraocular pressure (IOP) at the follow-up intervals.ResultsThe degree of neovascular membrane extent decreased from a preoperative mean of 226.95 ± 97.34 to 58.96 ± 84.12 at 1 week postoperatively and 31.3 ± 51.54 at 1 month postoperatively. The preoperative mean IOP was 58.7 ± 16.2 mmHg; it decreased to 20.8 ± 9.99 mmHg at 1 week, 18.47 ± 5.6 mmHg at 1 month, 22.65 ± 8.7 mmHg at 2 months, and 25.34 ± 6.806 mmHg at 3 months postoperatively ( P remained ≤0.001 throughout the course of follow-up). In addition, BCVA showed noticeable improvement during the course of follow-up; the mean preoperative BCVA logarithm of minimal angle of resolution (BCVA logMAR) was 1.47 ± 0.511, which significantly improved to 1.29 ± 0.55, 1.16 ± 0.58, 1.15 ± 0.6, and 1.3 ± 0.56 at 1 week and 1, 2, and 3 months, postoperatively, respectively.ConclusionCombined intravitreal and intracameral injection with bevacizumab followed by PRP can be considered to be a very effective and safe IOP-lowering technique in the case of neovascular glaucoma.
Zitieren
APA
Khattab, A., & Azmy, E. (2013). Combined intracameral and intravitreal bevacizumab injection in Neovascular Glaucoma. Journal of the Egyptian Ophthalmological Society. https://doi.org/10.4103/2090-0686.127340
Vancouver
Khattab A, Azmy E. Combined intracameral and intravitreal bevacizumab injection in Neovascular Glaucoma. Journal of the Egyptian Ophthalmological Society. 2013. doi:10.4103/2090-0686.127340
BibTeX
@article{Khattab2013,
author = {Khattab, Abeer and Azmy, Eman},
title = {Combined intracameral and intravitreal bevacizumab injection in Neovascular Glaucoma},
journal = {Journal of the Egyptian Ophthalmological Society},
year = {2013},
doi = {10.4103/2090-0686.127340}
}
EUVIMED